HK Recently Listed Stocks Watch | HJ SCIENCE-B (06132.HK) down 7.70%, 6.23 million cornerstone shares to be unblocked on 23 December

NewTimeSpace News, on 13 October 2026, innovative drug shares traded with a correction while HJ SCIENCE-B (06132.HK) weakened. As of 13:42, the company quoted HKD 33.780, down 7.70%.

On the news front, the company has no recent news of its own; within the sector, on 12 October 2026, INNOCARE (09969.HK) announced that its self-developed bispecific antibody ICP-B161, targeting TL1A and IL-23p19, has been approved by the relevant national authorities to commence clinical trials for the treatment of autoimmune diseases including inflammatory bowel disease. The drug can achieve an ultra-long half-life and support subcutaneous administration; preclinical studies showed that, in a TNBS-induced mouse colitis model, its in vivo efficacy at the same dose was superior to the corresponding TL1A monoclonal antibody, IL-23p19 monoclonal antibody and similar bispecific antibodies. There is currently no bispecific antibody targeting TL1A and IL-23p19 on the market worldwide.

In addition, on 13 October 2026, Ark Biosciences announced that the US Food and Drug Administration has approved the investigational new drug application for its self-developed long-acting anti-influenza drug-Fc conjugate AK0406, allowing the drug to directly enter a Phase II clinical trial for influenza prevention in the United States. The drug has shown broad-spectrum, highly active inhibition against both influenza A and B viruses in preclinical studies.

HJ SCIENCE-B (06132.HK) listed on the Main Board of the Hong Kong Stock Exchange on 23 June 2026 at an offer price of HKD 81.80, with 13,600,000 shares issued.

Regarding its shareholding structure, the lock-up period of all six cornerstone investors of the company is six months, with the nearest release date falling on 23 December 2026, when a total of 6,227,800 shares held by six cornerstone investors including Foresight Fund, Kaibo Future and LBC HK will be released from lock-up, representing 45.79% of the shares under the global offering and 8.46% of the company's total issued share capital immediately following completion of the global offering. In addition, the 12-month lock-up undertakings of the company's controlling shareholders (Dr Ji Jianxin, Chengdu Wenshao Enterprise Management Centre and Suzhou Jishitang Enterprise Management Centre, together holding 34,493,443 shares, or 46.87%) and its pre-IPO investors are expected to be released from lock-up in late June 2027.

In terms of financial performance, the company disclosed its first interim results after listing on 28 August 2026. For the first half of 2026, revenue was RMB 1.943 million, up 118.1% year on year; R&D expenses were RMB 46.255 million, up 13.1% year on year; loss for the period was RMB 73.475 million, widening 38.8% year on year; adjusted loss was RMB 47.302 million, narrowing 10.7% year on year; and basic and diluted loss per share was RMB 1.21. During the reporting period, the Phase II clinical trial of HJ787 for atopic dermatitis completed patient enrolment, and the pivotal Phase IIb clinical trial of HJ891 for non-small cell lung cancer also completed patient enrolment. As of 30 June 2026, the company had cash and cash equivalents of RMB 1.107 billion, up substantially from RMB 3.72 million at the end of 2025, mainly from the proceeds of the global offering. The company declared no interim dividend.

HJ SCIENCE-B (06132.HK) focuses on the research and development of small-molecule innovative therapies in immunology, metabolism and oncology as a clinical-stage biotechnology company. It has three core products, HJ787, HJ178 and HJ891, all self-developed Class 1 innovative drugs: HJ787 is a selective TYK2 inhibitor for topical and oral treatment of atopic dermatitis, acne vulgaris, neurodermatitis and psoriasis; HJ178 is an oral GLP-1 and GIP receptor agonist for type 2 diabetes and potentially overweight or obesity; and HJ891 is an oral KRAS G12C inhibitor for non-small cell lung cancer harbouring KRAS G12C mutations. In addition, the company has one other clinical-stage candidate, HJ197, and five preclinical candidates.